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Background: Pruritis caused by atopic dermatitis (AD) is not 
always well controlled by topical corticosteroid therapy, but 
use of tacrolimus often helps to soothe such intractable 
pruritis in clinical settings. Objective:  To determine the 
anti-pruritic efficacy of topical tacrolimus in treating AD in 
induction and maintenance therapy. Methods: Prior to the 
study, patients were randomly allocated into two groups, 
induction therapy followed by tacrolimus monotherapy 
maintenance, and induction therapy followed by emollient- 
only maintenance. In the induction therapy, the patients 
were allowed to use topical tacrolimus and emollients in 
addition to a low dose  (＜10 g/week) of topical steroids. 
Patients showing relief from pruritis were allowed to proceed 
to maintenance therapy. Recurrence of pruritis in 
maintenance therapy was examined as a major endpoint. 
Results: Two-thirds of patients (44/68; 64.7%) showed relief 
from pruritis after induction therapy. Pruritis recurred in 
23.8% (5/21) of the tacrolimus monotherapy group and in 
100% (21/21) of the emollient group during maintenance 
period, a difference that was statistically significant. Conclu-
sion: Use of topical tacrolimus is effective in controlling 
pruritis of AD compared to emollient. (Ann Dermatol 24(2) 
144∼150, 2012)
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INTRODUCTION
Atopic dermatitis (AD) is a common chronic or chroni-
cally relapsing, severely pruritic, and eczematous skin 
disease whose prevalence appears to have increased 
significantly in recent decades
1,2. The control of pruritis, a 
primary symptom of AD, is very important in its treatment 
since pruritis itself is an unpleasant sensation that often 
disturbs patients’ sleep. Additionally, incidental scratching 
exacerbates and sustains skin eruptions, thereby signifi-
cantly reducing patient quality of life. However, pruritis Tacrolimus as an Anti-pruritic Treatment
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Fig. 1. Flow diagram showing subjects’
progress. Patients were advance- 
allocated after registration, received 
introduction therapy (add-on tacro-
limus therapy), and the responders 
to the introduction therapy pro-
ceeded into maintenance therapy. 
There were several dropouts and one
refusal during the study. VAS: visual
analogue scale.
caused by AD is not readily controlled with clinically 
available oral antihistamines, probably due to the pre-
sence of many inflammatory pruritogenic factors other 
than histamine
3-5. Thus, one of the simplest and most 
practical answers is to reduce or eliminate skin inflam-
mation by the use of strong anti-inflammatory agents such 
as topical corticosteroids. Indeed, this strategy is effective 
in most cases in treating pruritis as well as skin inflam-
mations caused by AD
6. However, there are substantial 
numbers of patients undergoing topical corticosteroid 
therapy who still suffer from intractable pruritis and whose 
extensive scratching aggravates their dermatitis. Calci-
neurin inhibitors are a relatively new treatment for AD, 
and orally administered cyclosporine has been reported 
effective in treating refractory pruritis in patients with AD
7. 
Similarly, the anti-pruritic effects of topical calcineurin 
inhibitors have also been reported
8. Thus, the purpose of 
this study was to further evaluate the anti-pruritic efficacy 
of topical tacrolimus, a calcineurin inhibitor, in the 
treatment of patients with AD in inductive and main-
tenance treatment.
MATERIALS AND METHODS
Inclusion/Exclusion
Patients with AD who were ＞10 years old and whose 
visual analogue scale (VAS)-itch scores (max=100) were 
30∼80 were recruited after written informed consent was 
obtained. Patients whose VAS-itch scores were ＞80 were 
excluded because of their desperate need for anti-pruritic 
treatment including antihistamines or more potent systemic 
anti-inflammatory treatment. Conversely, patients whose 
VAS-itch scores were ＜30 were excluded because of their 
lesser need for additional anti-pruritic therapy and the 
limited window in assessing pruritis improvement. Patients 
who had been treated with orally administered cortico-
steroids, cyclosporine, or antihistamines within two weeks 
prior to the registration were also excluded because of S Takeuchi, et al
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Table 1. Baseline values of patients
Total (n=70) Completion of study  (n=42)
Tacrolimus 
monotherapy-
allocated (n=35)
Emollient-
allocated
(n=35)
Total
Tacrolimus 
monotherapy 
(n=21)
Emollient 
(n=21) Total
Gender, numbers (%)
  Male    17 (48.6)   20 (57.1)   37 (52.9)   12 (57.1)    9 (42.9)   21 (50.0)
  Female   18 (51.4)   15 (42.9)   33 (47.1)    9 (42.9)   12 (57.1)   21 (50.0)
Age (yr)
  Mean (SD) 30.5 (13.2) 30.8 (11.9) 30.7 (12.5) 31.3 (13.6) 31.3 (13.3) 31.3 (13.3)
  10∼24, numbers (%)   12 (34.3)   14 (40.0)   26 (37.1)    9 (42.9)    6 (28.6)   15 (35.7)
  25∼35, numbers (%)   13 (37.1)   10 (28.6)   23 (32.9)    5 (23.8)    8 (38.1)   13 (31.0)
  36∼64, numbers (%)   10 (28.6)   11 (31.4)   21 (30.0)    7 (33.3)    7 (33.3)   14 (33.3)
Institution, numbers (%)
  Kyushu University   14 (40.0)   14 (40.0)   28 (40.0)   12 (57.1)    9 (42.9)   21 (50.0)
  University of Tokyo   12 (34.3)   13 (37.1)   25 (35.7)    4 (19.0)    8 (38.1)   12 (28.6)
  National Center for Child   3 (8.6)    4 (11.4)    7 (10.0)   2 (9.5)   2 (9.5)   4 (9.5)
   Health and Development
   (Allergy Division)
  Social Insurance Chuo   1 (2.9)   2 (5.7)   3 (4.3)   0 (0.0)   2 (9.5)   2 (4.8)
   General Hospital
  Saitama Medical University   2 (5.7)   0 (0.0)   2 (2.9)   2 (9.5)   0 (0.0)   2 (4.8)
  National Center for Child   1 (2.9)   0 (0.0)   1 (1.4)   1 (4.8)   0 (0.0)   1 (2.4)
   Health and Development
   (Dermatology Division)
  St. Marianna University   1 (2.9)   1 (2.9)   2 (2.9) 0 0 0
   School of Medical Hospital
  Hiroshima University    1 (2.9)   1 (2.9)   2 (2.9) 0 0 0
Numbers (%)
  Complications -yes-   19 (54.3)   20 (57.1)   39 (55.7)   11 (52.4)   11 (52.4)   22 (52.4)
  Past history -yes-   21 (60.0)   26 (74.3)   47 (67.1)   13 (61.9)   16 (76.2)   29 (69.0)
  Family history* -yes-   15 (46.9)   24 (72.7)   39 (60.0)    8 (42.1)   14 (70.0)   22 (56.4)
Complications (details)
  Asthma   10 (31.3)   10 (30.3)   20 (30.8)    6 (28.6)    6 (28.6)   12 (28.6)
  Allergic rhinitis   10 (28.6)   18 (51.4)   28 (40.0)    6 (28.6)   10 (47.6)   16 (38.1)
  Allergic conjunctivitis   1 (2.9)   0 (0.0)   1 (1.4)   1 (4.8)   0 (0.0)   1 (2.4)
  Scoliosis   1 (2.9)   0 (0.0)   1 (1.4) 0 0 0
  Autistic tendency   1 (2.9)   0 (0.0)   1 (1.4) 0 0 0
Medical history
  Asthma   14 (40.0)   18 (51.4)   32 (45.7)    9 (42.9)   11 (52.4)   20 (47.6)
  Allergic rhinitis   10 (28.6)   17 (48.6)   27 (38.6)    6 (28.6)   10 (47.6)   16 (38.1)
  Pollen allergy   0 (0.0)   1 (2.9)   1 (1.4)   0 (0.0)   1 (4.8)   1 (2.4)
  Family history
  Atopic dermatitis   12 (37.5)   17 (51.5)   29 (44.6)    6 (31.6)   10 (50.0)   16 (41.0)
  Asthma    4 (12.5)    5 (15.2)    9 (13.8)    2 (10.5)    2 (10.0)    4 (10.3)
  Allergic rhinitis   2 (6.3)    8 (24.2)   10 (15.4)   1 (5.3)    6 (30.0)    7 (17.9)
  Pollen allergy   0 (0.0)   2 (6.1)   2 (3.1)   0 (0.0)   1 (5.0)   1 (2.6)
Treatment within the last month
  Topical corticosteroids   30 (85.7)   26 (74.3)   56 (80.0)   18 (85.7)   14 (66.7)   32 (76.2)
  Topical tacrolimus   19 (54.3)   19 (54.3)   38 (54.3)   13 (61.9)   11 (52.4)   24 (57.1)
  Oral antihistamines   10 (28.6)   12 (34.3)   22 (31.4)    5 (23.8)    6 (28.6)   11 (26.2)
  Emollients (heparin)   3 (8.6)   3 (8.6)   6 (8.6)   2 (9.5)   2 (9.5)   4 (9.5)
SD: standard deviation. *65 of 70 in Test 1 and all subjects in Test 2 answered this question.
their potential influence on pruritis.
Study design
All of the patients received induction (1∼4 weeks) and 
maintenance (＞4 weeks) therapy. Prior to the study, 
patients were randomly allocated in advance into two 
groups: patients who received topical tacrolimus mono-
therapy as maintenance therapy after induction therapy 
and patients who received emollient only for maintenance 
therapy after induction therapy. In the induction therapy, Tacrolimus as an Anti-pruritic Treatment
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Fig. 2. Change in visual analogue scale (VAS)-itch score and disease severity after add-on tacrolimus therapy. (A) Pruritis (mean VAS-itch
score - standard deviation) reduced after add-on topical tacrolimus therapy. (B) There was no statistical difference in mean VAS-itch
score between responders and non-responders before the add-on therapy. (C) There was a significant decrease in VAS-itch score in
responders after the add-on therapy. (D) SCORing Atopic Dermatitis (SCORAD) score reduced after the add-on topical tacrolimus
therapy.
all of the patients were treated with topical tacrolimus (of 
0.03% for patients ＜16 years old and of 0.1% otherwise) 
and emollients twice daily in addition to their usual 
topical corticosteroid treatment (maximum use, 10 g/week), 
and change of VAS-itch score was examined. Patients who 
showed a reduced VAS-itch score by ＞20 points were 
considered to show relief from pruritis, while only such 
induction therapy responders proceeded into maintenance 
treatment. In maintenance therapy, recurrence of pruritis, 
mean change of VAS-itch scores, and the percentage of 
patients with pruritis recurrence were measured. Patients 
who showed increased VAS-itch scores of ＞20 points 
were categorized as suffering from pruritis recurrence in 
maintenance treatment. Secondarily, skin severity score 
was monitored using the SCORing Atopic Dermatitis 
(SCORAD) score
9. This study was an open label, 
randomized, multi-center study and was approved by the 
internal ethical review boards of Kyushu University and 
other institutions.
Statistical analysis
The confidence interval (CI) for the proportion of subjects 
who experienced pruritis relief was estimated in the 
induction therapy using Fisher’s exact method assuming a 
binomial distribution, while changes in VAS-itch score 
and SCORAD were assessed using the paired t-test. The 
cumulative proportion of pruritis recurrence was esti-
mated using the Kaplan-Meier method, while the CI was 
estimated using Greenwood’s method in maintenance 
treatment. The percentage difference in pruritis recurrence 
between the two groups was assessed using Fisher’s exact 
test. The mean difference between VAS-itch score and its 
95% CI were estimated using analysis of covariance 
(ANCOVA). The time elapsed before pruritis recurrence 
was assessed using the stratified log-rank test, with 
institutions divided into “Kyushu University,” “University S Takeuchi, et al
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Fig. 3. Cumulative recurrence of pruritis in maintenance therapy.
Tacrolimus monotherapy group (solid line) showed significantly
much lower recurrence of pruritis compared to that of the 
emollient group (dotted line).
Table 2. Median time to pruritis recurrence in maintenance
therapy
Time to recurrence
  Tacrolimus monotherapy ＞28 days
  Emollient    3 days
Fig. 4. Efficacy of tacrolimus monotherapy in maintenance 
therapy. The emollient group showed more pruritis than the 
tacrolimus monotherapy group at the end of maintenance 
therapy. VAS: visual analogue scale.
Table 3. Change of pruritis (mean [standard deviation]) after 
maintenance therapy 
Before After
Tacrolimus monotherapy 28.1 (15.4) 29.6 (20.9)
Emollient 19.3 (16.7) 50.7 (17.0)
of Tokyo,” and “other institutions.” 
RESULTS
A total of 70 patients with AD were registered, 68 of 
whom completed induction therapy (Fig. 1). A total of 44 
of the 68 patients experienced pruritis relief (64.7%; 95% 
CI, 53.1∼76.4%), while 43 of the 44 responders pro-
ceeded to maintenance therapy. The median and mean 
(standard deviation, SD) of the induction therapy period 
among the 43 patients were 15 days and 17.9 (7.1) days, 
respectively. Twenty-one patients each in the tacrolimus 
monotherapy group and the emollient group completed 
the maintenance treatment. No marked bias was apparent 
in the baseline data of the patients who were registered 
compared to those who completed this whole study 
(Table 1). 
In the induction therapy, mean VAS-itch score (SD) 
decreased from 51.1 (16.6) to 32.3 (22.1) (Fig. 2A), while 
the mean difference, 18.8 (95% CI, 13.5∼24.1), was 
statistically significant (p＜0.0001). There was no statistical 
difference in mean VAS-itch score between responders 
and non-responders before the induction therapy (Fig. 2B), 
but there was a significant decrease of VAS-itch in res-
ponders after treatment (Fig. 2C). Data on disease severity 
(SCORAD) after the induction therapy were obtained from 
50 of the 68 subjects who completed treatment (43 of the 
44 pruritis-responders and 7 of the 24 non-responders). 
Mean SCORAD (SD) of the 50 subjects decreased from 
29.1 (11.1) to 17.3 (10.6) (Fig. 2D), and the mean 
difference of 11.8 (95% CI, 9.0∼14.7) was statistically 
significant (p＜0.0001). 
Cumulative itch recurrence in the tacrolimus monotherapy 
maintenance group and emollient maintenance group at 
day 28 was 23.8% (95% CI, 10.7∼52.9%) and 100%, 
respectively in maintenance treatment (Fig. 3), and the 
difference between the two groups was statistically signi-
ficant (p＜0.0001). The median time to pruritis recur-
rence in the tacrolimus monotherapy group and the 
emollient group was ＞28 days and 3 days (95% CI, 2∼5 
days), respectively (Table 2). The mean VAS-itch score in 
the tacrolimus monotherapy group was well controlled as 
shown by values of 28.1 (15.4) at the start and 29.6 (20.9) 
at the end of maintenance treatment, while that in the 
emollient group significantly increased from 19.3 (16.7) to 
50.7 (17.0) (Table 3). The mean change in VAS-itch scores 
was 1.50 (3.30) in the tacrolimus monotherapy and 31.4 
(2.59) in the emollient group, respectively, in maintenance 
treatment (Fig. 4), and the difference, 28.6 (95% CI, 19.8
∼37.5), was statistically significant (p＜0.0001).
A transient burning sensation by topical tacrolimus, the 
only distinguished side effect, was recorded in 32 of 69 Tacrolimus as an Anti-pruritic Treatment
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Fig. 5. Change of SCORing Atopic Dermatitis (SCORAD) in 
induction therapy between treatment-responding (blue circle) 
and non-responding patients (red circle) in induction therapy. 
Forty-three treatment-responding patients showed significantly 
reduced SCORAD compared to that of 7 non-responding patients
in induction therapy as assessed by analysis of covariance 
(p=0.001). 
patients (46.3%, excluding one dropout patient who never 
returned after initial registration) in the induction therapy. 
The other minor side effect was acne/folliculitis (3 cases, 
4.3%), herpes simplex (1 case, 1.4%), wart (1 case, 1.4%), 
and the common cold (2 cases, 2.9%) throughout the 
study period.
DISCUSSION
In the induction therapy of this study, patients were 
allowed to use topical tacrolimus and emollients in 
addition to low-dose application (＜10 g/week) of topical 
steroids. Almost two-thirds of the patients with AD experi-
enced pruritis relief after the induction therapy. In these 
responsive patients, sequential maintenance by topical 
tacrolimus monotherapy was found to be significantly 
effective in controlling pruritis caused by AD compared 
with emollient only. 
Orally administered cyclosporine appeared to effectively 
treat intractable pruritis in patients with AD as previously 
mentioned
7. However, various adverse effects, such as 
systemic immune suppression, hypertension, headache 
and possible renal failure, should be considered and 
carefully monitored before and during administration. 
Topical tacrolimus, on the other hand, can basically avoid 
all of these undesirable adverse effects and is therefore 
more suitable for use in daily clinics, except for possible 
local immune suppression of the skin. However, one of 
our earlier studies and another report showed that topical 
tacrolimus was not associated with an increase in cuta-
neous infection
10,11. Ultraviolet therapy is another option 
for treating intractable pruritis in patients with AD
12, but it 
carries the possible risk of developing skin cancer in the 
long run
13, raising a concern about its use, particularly in 
infants.
Hon et al.
14 evaluated the clinical efficacy of topical tacro-
limus for reducing the sensation of pruritis in children 
with AD. Three boys and four girls with AD were treated 
with topical tacrolimus for a consecutive two-week period 
after a one-week run-in. Nocturnal scratching activity 
measured using a DigiTrac movement recorder was 
reduced from 115.0 g/min to 71.5 g/min (p=0.028) after 
two weeks of treatment.
Such anti-pruritic effects of topical tacrolimus are thought 
to be due to its anti-inflammatory action considering the 
fact that the efficacy of 0.1% tacrolimus ointment was 
similar to that of 0.1% hydrocortisone butyrate ointment 
or 0.12% betamethasone valerate ointment when applied 
for three weeks in adults
15,16. However, pruritis is not 
always readily relieved even after topical application of 
more potent corticosteroids in clinical settings. Several 
unique characteristics of tacrolimus that appear to be 
related to its anti-pruritic effects, such as inhibition of the 
epidermal sensory nerve extension
17, transient release of 
substance P from sensory nerve endings
18, and suppression 
of mast cell degranulation
19 have been reported. There is 
currently no conclusive answer as to what governs the 
mechanism of anti-pruritic action of tacrolimus; however, 
one important fact is that topical tacrolimus does have an 
anti-pruritic property that topical corticosteroids lack
17. 
We reproduced these results in a very similar experi-
mental setting and extended the findings that the curious 
anti-pruritic effects of tacrolimus might not be simply due 
to its anti-inflammatory effects or anti-epidermal nerve 
extension effects
20. In this study, the treatment responders 
(patients with decreased pruritis) showed a better change 
in SCORAD (disease severity) than non-responders in the 
induction therapy when data available were analyzed by 
ANCOVA (Fig. 5). However, we cannot determine from 
this whether the improved disease severity might come 
from less itching/scratching by the direct action of topical 
tacrolimus or that improved disease severity resulted in 
less production of various inflammatory pruritogens to 
bring about less pruritis. Anyhow, controlling 
itching/scratching is important in the formation of allergic 
skin reaction
21, and further investigations will be needed 
to precisely identify the mechanism of action of anti- 
pruritic effects by anti-inflammatory agents.
Finally, this is an open study; therefore the possibility of a 
placebo effect (no exact vehicle control was used) should S Takeuchi, et al
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also be taken into consideration, such as possible anti- 
pruritic effects by the vehicle as an emollient. However, 
the use of emollients was allowed in both the tacrolimus 
monotherapy group and emollient group in maintenance 
treatment, thereby lessening this possibility. 
In conclusion, topical tacrolimus is well tolerated (68/70 
patients were able to complete the induction therapy) and 
significantly effective in controlling intractable pruritis 
during induction and maintenance therapy for patients 
with AD.
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